Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: In this Determining Appropriate Sensitivity Tests webcast, explore sensitivity testing effectiveness, the important difference between sensitivity and stress testing and more. Understanding sensitivity testing is critical to actuarial work, especially in order to properly assess and evaluate risk factors. Come explore approached to sensitivity tests and effective evaluations of sensitivity test results in order to elevate your knowledge within the actuarial science field.

Description: Learn how modernization of data, models, and technology are influencing workflows. This webcast will address how workflows are changing in response to new regulatory requirements and the impacts the changes have on modeling and end-to-end future state operating models. Industry leading actuaries will discuss: How team collaboration can increase quality and speed of reporting to internal and external stakeholders How to strengthen controls and compliance frameworks across finance and actuarial departments How to modernize actuarial input/output for strategic analysis and insights How to attract and retain top talent by improving opportunities for actuaries There will also be dedicated time to ask questions of those who have made the transition.

Description: The topics of ESG (Environmental, Social & Corporate Governance) and sustainability are an increasing area of focus for insurance companies, and thus actuaries. This webcast provides a primer on these topics along with considerations for US valuation actuaries and their evolution in European insurance markets.

Description: Learn from panelists from different companies as they come together to discuss their experiences.

Description: 2021 ImpACT Conference - Session 12C: The Evolving Role of Actuaries in a Principles-Based World 10.29.21 Recording

Description: The ASU 2018-12 guidance, otherwise known as long-duration targeted improvements (LDTI), establishes a significant new category of benefit features called market risk benefits (MRB) that protect the contractholder from other-than-nominal capital market risk and expose the insurer to that risk. Insurers will have to measure market risk benefits at fair value. There are a few examples of MRB, Including the most common one— MGxBs on variable and indexed annuities. This change may bring significant volatility to earnings of these GMxB policies that are currently valued under the insurance accrual model (such as SOP 03-1). How to analyze the changes in volatility in MRBs became the natual question for many companies that haven't been valuing them on fair value basis. Besides the GMxBs, have you wondered when or if the guaranteed annuitization options offered by your company have other-than-norminal risk? By attending the session, you will: · Understand different types of MRBs. · Learn about ways to analyze the changes in volatility in MRBs from SOP 03-1. · Understand the accounting of MRB change for a contract under reinsurance going through spread and liability assumption updates. · Understand when the guaranteed annuitization options become MRB and how to evaluate that.

Description: 2021 ImpACT Conference - Session 6C: Reshaping the Roles of Actuaries - A Case Study 10.27.21 Recording

Description: After the arduous journeys IFRS 17 filers underwent to implement the standard, it would only make sense for insurers to seek the best return on their investment post effective date of 1/1/2023. Many insurers are now embarking a new phase of the journey that involves wrapping up any unfinished business as they might have taken a minimum compliance route to finish implementation and thinking about the knock-on effects the new standard has on the way they carry out business and perform financial reporting.